Roivant Sciences Ltd. (NASDAQ:ROIV) COO Eric Venker Sells 100,000 Shares

Roivant Sciences Ltd. (NASDAQ:ROIV) COO Eric Venker sold 100,000 shares of the company’s stock in a transaction dated Monday, October 21st. The stock was sold at an average price of $11.65, for a total value of $1,165,000.00. Following the completion of the sale, the chief operating officer now directly owns 617,470 shares of the company’s stock, valued at $7,193,525.50. The trade was a 0.00 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink.

Roivant Sciences Price Performance

Shares of ROIV traded up $0.11 during trading hours on Tuesday, hitting $11.73. 2,506,126 shares of the company were exchanged, compared to its average volume of 5,981,306. The company has a market capitalization of $8.67 billion, a PE ratio of 2.32 and a beta of 1.24. The company has a debt-to-equity ratio of 0.05, a current ratio of 27.91 and a quick ratio of 27.91. The firm has a fifty day simple moving average of $11.79 and a 200-day simple moving average of $11.22. Roivant Sciences Ltd. has a one year low of $8.24 and a one year high of $13.06.

Roivant Sciences (NASDAQ:ROIV) last released its quarterly earnings data on Thursday, August 8th. The company reported $0.12 earnings per share for the quarter, topping the consensus estimate of ($0.21) by $0.33. The business had revenue of $55.10 million during the quarter, compared to analyst estimates of $30.72 million. Roivant Sciences had a negative return on equity of 17.23% and a net margin of 2,991.75%. The company’s revenue was up 155.1% compared to the same quarter last year. During the same period last year, the company posted ($0.38) EPS. As a group, sell-side analysts predict that Roivant Sciences Ltd. will post -1.14 earnings per share for the current year.

Wall Street Analyst Weigh In

A number of brokerages have recently weighed in on ROIV. HC Wainwright reiterated a “buy” rating and set a $18.00 price target on shares of Roivant Sciences in a research report on Thursday, September 19th. Piper Sandler increased their price target on Roivant Sciences from $20.00 to $22.00 and gave the stock an “overweight” rating in a research report on Wednesday, July 10th. Cantor Fitzgerald reiterated an “overweight” rating on shares of Roivant Sciences in a research report on Thursday, September 19th. Finally, Bank of America raised their target price on Roivant Sciences from $12.00 to $12.50 and gave the company a “neutral” rating in a research report on Wednesday, September 11th. One investment analyst has rated the stock with a hold rating and nine have given a buy rating to the company. According to MarketBeat.com, Roivant Sciences presently has an average rating of “Moderate Buy” and a consensus target price of $17.39.

Institutional Trading of Roivant Sciences

Hedge funds and other institutional investors have recently modified their holdings of the company. Allspring Global Investments Holdings LLC grew its stake in shares of Roivant Sciences by 1,207.5% in the 1st quarter. Allspring Global Investments Holdings LLC now owns 70,410 shares of the company’s stock valued at $742,000 after purchasing an additional 65,025 shares during the period. State of Michigan Retirement System acquired a new position in Roivant Sciences during the first quarter valued at approximately $853,000. State of Alaska Department of Revenue bought a new position in shares of Roivant Sciences during the first quarter worth $389,000. Principal Financial Group Inc. boosted its position in shares of Roivant Sciences by 3,413.9% during the first quarter. Principal Financial Group Inc. now owns 1,274,737 shares of the company’s stock worth $13,436,000 after purchasing an additional 1,238,460 shares in the last quarter. Finally, Privium Fund Management B.V. boosted its position in shares of Roivant Sciences by 104.4% during the first quarter. Privium Fund Management B.V. now owns 567,795 shares of the company’s stock worth $5,985,000 after purchasing an additional 290,000 shares in the last quarter. 64.76% of the stock is currently owned by hedge funds and other institutional investors.

About Roivant Sciences

Roivant Sciences Ltd., a commercial-stage biopharmaceutical company, engages in the development and commercialization of medicines for inflammation and immunology areas. The company provides Vants, a model to develop and commercialize its medicines and technologies focusing on biopharmaceutical businesses, discovery-stage companies, and health technology startups.